What Is CBG? The Mother Cannabinoid Explained

Close-up of a hemp plant with young leaves and budding growth

CBG (cannabigerol) is sometimes called the “mother of all cannabinoids” — and for good reason. Every other cannabinoid in the cannabis plant, including CBD and THC, starts as CBG before enzymes convert it into other compounds. Understanding CBG helps explain how the cannabis plant works and why this minor cannabinoid is attracting serious research attention.

What Is CBG?

CBG (cannabigerol) is a non-psychoactive cannabinoid found in small concentrations in most cannabis and hemp plants. It is the precursor compound from which CBD, THC, and CBC are all synthesized within the plant. Because the plant converts most CBG into other cannabinoids as it matures, CBG is present in very low quantities in typical hemp — usually less than 1% by weight.

This scarcity makes CBG more expensive to extract than CBD, which is why CBG products typically cost more. However, selective breeding programs have produced high-CBG hemp strains, and extraction technology is improving.

How CBG Works

Unlike CBD, which interacts indirectly with CB1 and CB2 receptors, CBG binds directly to both receptors. It also interacts with:

  • Alpha-2 adrenergic receptors — involved in pain and blood pressure regulation
  • Serotonin 5-HT1A receptors — relevant to anxiety and mood
  • TRP channels — involved in pain and inflammation signaling

This broader receptor profile gives CBG a distinct set of potential effects that complement — and sometimes differ from — CBD.

Potential Benefits of CBG: What the Research Shows

Antibacterial Properties

A 2020 study published in ACS Infectious Diseases found CBG to be highly effective against MRSA — a drug-resistant bacterial infection that is notoriously difficult to treat. CBG outperformed several existing antibiotics in laboratory conditions. While this has not yet been validated in human clinical trials, it is one of the most striking findings in cannabinoid research.

Neuroprotection

Research published in Neurotherapeutics found that CBG had neuroprotective effects in animal models of Huntington’s disease — protecting neurons from degeneration better than CBD in the same model. Studies on Parkinson’s disease models have also shown promising neuroprotective activity.

Inflammatory Bowel Disease

A 2013 study in Biochemical Pharmacology found that CBG reduced inflammation in mouse models of IBD (inflammatory bowel disease) and significantly reduced the production of nitric oxide and reactive oxygen species. This makes CBG a promising candidate for conditions like Crohn’s disease and ulcerative colitis — and it complements the evidence we already have for CBD and gut health.

Glaucoma

One of the earliest CBG findings was its ability to reduce intraocular pressure — a key factor in glaucoma. This was documented as far back as 1990 in animal studies and remains one of CBG’s most discussed potential applications.

CBG vs CBD: Key Differences

FeatureCBGCBD
Receptor bindingDirect CB1 + CB2 agonistIndirect modulation
Abundance in hempLess than 1%Up to 20%
CostHigherLower
Research volumeEarly-stageExtensive
Psychoactive?NoNo
Best studied forAntibacterial, IBD, neuroprotectionPain, anxiety, sleep, epilepsy

CBG and CBD are not competing — they are complementary. Full spectrum CBD products already contain trace CBG alongside CBD and other minor cannabinoids, contributing to the entourage effect.

Frequently Asked Questions

What is CBG good for?

CBG has shown promise for antibacterial activity (including MRSA), neuroprotection, inflammatory bowel disease, and glaucoma in preclinical studies. Human trials are still limited, but CBG’s receptor profile suggests real complementary benefits alongside CBD.

Is CBG better than CBD?

They have different strengths. CBD has far more human research for anxiety, pain, and sleep. CBG has unique antibacterial and neuroprotective properties. They work best together — which is exactly what full spectrum products provide.

Does CBG make you high?

No. CBG is non-psychoactive despite binding directly to CB1 receptors. It does not produce a high at any known supplement dose.

Leave a Comment